Lymphoma (includes NHL, HL, CNS Lymphoma)
Featured Articles
(ASCO in Action) Aug 8, 2018 - On Aug. 8, 2018, the Food and Drug Administration approved mogamulizumab-kpkc (Poteligeo, Kyowa Kirin, Inc.) for adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. The approval of mogamulizumab-kpkc, a CC chemokine...
Read Article
(Genetic Engineering & Biotechnology News) Aug 2, 2018 - Epizyme said today it will halt a Phase II clinical trial assessing its lead candidate, the cancer treatment tazemetostat in relapsed and/or refractory diffuse large B-cell lymphoma (r/r DLBCL). The trial halt comes more than three months after the FDA imposed a partial...
Read Article
Latest Articles
August 14, 2018
August 13, 2018
August 09, 2018
August 08, 2018
August 07, 2018
July 26, 2018
July 24, 2018
July 23, 2018
View More
News Commentary
Editor Image
09 Apr, 2018 | by Winston Wong, PharmD
CMS has set the reimbursement for their near normal outpatient rate, thus CMS...
View Comment
Editor Image
15 Mar, 2018 | by H. Jack West, MD
This presentation of data from KEYNOTE-189, CheckMate-227, IMpower150, and some...
View Comment
View More
OBR Green
There are no Lymphoma (includes NHL, HL, CNS Lymphoma) OBR Green articles.
OBR Blog
There are no Lymphoma (includes NHL, HL, CNS Lymphoma) blog entries.